SS
CRSP icon

Simplicity Solutions’s CRISPR Therapeutics CRSP Stock Holding History

Simplicity Solutions’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,840
Closed -$442K – 631
2021
Q4 		$442K Buy
5,840
+2,893
+98% +$253K 0.05% 420
2021
Q3 		$330K Buy
2,947
+166
+6% +$20.8K 0.05% 393
2021
Q2 		$450K Sell
2,781
-1,438
-34% -$175K 0.09% 250
2021
Q1 		$514K Buy
+4,219
New +$637K 0.11% 193

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Simplicity Solutions's CRSP Position: Q1 2022 in Review

Simplicity Solutions sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 5,840 shares — an estimated $442K sold.

Simplicity Solutions first reported a position in CRSP in Q1 2021 and held it in 4 quarters. The position peaked at $514K in Q1 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

  • Simplicity Solutions reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Simplicity Solutions sold 5,840 CRISPR Therapeutics shares in Q1 2022, an estimated $442K.
  • Simplicity Solutions first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 4 quarters.
  • Simplicity Solutions's CRISPR Therapeutics position peaked at $514K in Q1 2021.
  • 447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Simplicity Solutions's 13F filing for Q1 2022, filed 20 May 2022.